Trial Details
Not RecruitingBasic Information
| Clinical ID | c5464 |
|---|---|
| Identifier | ACTRN12619001373167 |
| Trial Title | Quercetin as an Adjunct to Primary Sclerosing Cholangitis Therapy with 5-ASA through Inhibition of N-acetylation |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NULL |
|---|---|
| Conditions | primary sclerosing cholangitis;inflammatory bowel disease;ulcerative colitis; primary sclerosing cholangitis inflammatory bowel disease ulcerative colitis;Oral and Gastrointestinal - Inflammatory bowel disease;Oral and Gastrointestinal - Other |
| Interventions | Pharmacokinetic Pilot StudyMesalazine (5-ASA) is an effective first-line therapy for patients with UC however there are no reports, positive or negative, of efficacy in PSC. 5-ASA is known to be rapidly N-acetylated once it is absorbed in the colo |
Participant Information
| Sponsor | IBD Clinical Trials Unit, Mater Research Ltd. |
|---|---|
| City | NULL |
| Country/Region | Australia |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, ELDER, OLDER_ADULT |
Study Design
| Study Type | Interventional |
|---|---|
| Phase | EARLY_PHASE1 |
Time Information
| Start Date | NULL |
|---|---|
| Primary Completion Date | NULL |
| Completion Date | NULL |